These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 39096929)

  • 21. Development and testing of an alternative responder definition for EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI).
    Wratten S; Abetz-Webb L; Arenson E; Griffiths P; Bowman S; Hueber W; Ndife B; Kuessner D; Goswami P
    RMD Open; 2023 Mar; 9(1):. PubMed ID: 36931685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and Application of the Placebo Response Model in Clinical Trials for Primary Sjögren's Syndrome.
    Wang ZZ; Zheng QS; Liu HX; Li LJ
    Front Immunol; 2021; 12():783246. PubMed ID: 34868062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
    Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
    Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and safety of abatacept for the treatment of patients with primary Sjögren's syndrome.
    Machado AC; Dos Santos LC; Fidelix T; Lekwitch I; Soares SB; Gasparini AF; Augusto JV; Junior NC; Trevisani VFM
    Clin Rheumatol; 2020 Jan; 39(1):243-248. PubMed ID: 31420813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.
    De Vita S; Quartuccio L; Seror R; Salvin S; Ravaud P; Fabris M; Nocturne G; Gandolfo S; Isola M; Mariette X
    Rheumatology (Oxford); 2015 Dec; 54(12):2249-56. PubMed ID: 26242856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
    Deodhar A; Gottlieb AB; Boehncke WH; Dong B; Wang Y; Zhuang Y; Barchuk W; Xu XL; Hsia EC;
    Lancet; 2018 Jun; 391(10136):2213-2224. PubMed ID: 29893222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Kimball AB; Jemec GBE; Sayed CJ; Kirby JS; Prens E; Ingram JR; Garg A; Gottlieb AB; Szepietowski JC; Bechara FG; Giamarellos-Bourboulis EJ; Fujita H; Rolleri R; Joshi P; Dokhe P; Muller E; Peterson L; Madden C; Bari M; Zouboulis CC
    Lancet; 2024 Jun; 403(10443):2504-2519. PubMed ID: 38795716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Traditional Chinese medicine compound ShengJinRunZaoYangXue granules for treatment of primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled clinical trial.
    Hu W; Qian X; Guo F; Zhang M; Lyu C; Tao J; Gao Z; Zhou Z
    Chin Med J (Engl); 2014; 127(15):2721-6. PubMed ID: 25146603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
    Shao Q; Wang S; Jiang H; Liu L
    Scand J Rheumatol; 2021 Mar; 50(2):143-152. PubMed ID: 33118847
    [No Abstract]   [Full Text] [Related]  

  • 32. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.
    Silverberg JI; Wollenberg A; Reich A; Thaçi D; Legat FJ; Papp KA; Stein Gold L; Bouaziz JD; Pink AE; Carrascosa JM; Rewerska B; Szepietowski JC; Krasowska D; Havlíčková B; Kalowska M; Magnolo N; Pauser S; Nami N; Sauder MB; Jain V; Padlewska K; Cheong SY; Fleuranceau Morel P; Ulianov L; Piketty C;
    Lancet; 2024 Aug; 404(10451):445-460. PubMed ID: 39067461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
    Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
    Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Papp KA; Weinberg MA; Morris A; Reich K
    Lancet; 2021 Apr; 397(10284):1564-1575. PubMed ID: 33894834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
    Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W
    Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).
    Seror R; Theander E; Brun JG; Ramos-Casals M; Valim V; Dörner T; Bootsma H; Tzioufas A; Solans-Laqué R; Mandl T; Gottenberg JE; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Valesini G; Bartoloni E; Saraux A; Tomsic M; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Vitali C; Mariette X; Bowman SJ;
    Ann Rheum Dis; 2015 May; 74(5):859-66. PubMed ID: 24442883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren's Syndrome: A Randomized Clinical Trial.
    Posada J; Valadkhan S; Burge D; Davies K; Tarn J; Casement J; Jobling K; Gallagher P; Wilson D; Barone F; Fisher BA; Ng WF
    Arthritis Rheumatol; 2021 Jan; 73(1):143-150. PubMed ID: 32798283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study.
    Lähdeaho ML; Scheinin M; Vuotikka P; Taavela J; Popp A; Laukkarinen J; Koffert J; Koivurova OP; Pesu M; Kivelä L; Lovró Z; Keisala J; Isola J; Parnes JR; Leon F; Mäki M
    Lancet Gastroenterol Hepatol; 2019 Dec; 4(12):948-959. PubMed ID: 31494096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
    Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.
    Kedor C; Zernicke J; Hagemann A; Gamboa LM; Callhoff J; Burmester GR; Feist E
    Clin Rheumatol; 2016 Sep; 35(9):2203-10. PubMed ID: 27470087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.